Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Boston Scientific completes enrollment of MADIT-CRT defibrillator trial

Boston Scientific : 24 April, 2008  (Company News)
Boston Scientific has been completed enrollment for the Multicentre Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT).
he trial includes 1,820 patients and examines the potential benefits of Boston Scientific cardiac resynchronisation therapy defibrillators (CRT-Ds) in a new population of heart failure patients.

The trial is the latest in a series of landmark randomised clinical trials sponsored by Boston Scientific's Cardiac Rhythm Management group, following in the tradition of MADIT, MADIT II and COMPANION.

MADIT-CRT is designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors and in those with other forms of impaired heart function. The trial may demonstrate if earlier intervention with CRT-D therapy can slow a patient's progression from early-stage heart failure (as defined by the New York Heart Association as Class I and II) to late-stage heart failure (Class III and IV).

'This study builds on the observations made in the COMPANION trial, which evaluated the benefits of CRT-D therapy in patients with late-stage, symptomatic heart failure,' said Arthur Moss, MD, professor of medicine at the University of Rochester, New York, and principal investigator of MADIT-CRT.

'If positive, this trial may address the still unanswered question about the potential of resynchronization defibrillator therapy to inhibit the clinical progression of heart failure through earlier intervention.'

'Boston Scientific is proud to sponsor MADIT-CRT, an important continuation of more than a decade of MADIT family trials,' said Jim Tobin, president and chief executive officer of Boston Scientific. 'This robust study design was created by leading cardiologists and is supported by medical science with appropriate endpoints to determine whether CRT-Ds can slow the progression of heart failure in Class I and II patients.'

Approximately 70 percent of all heart failure patients fall into Class I or II. Nearly 22 million people worldwide, including approximately 5.5 million Americans, currently suffer from some form of heart failure. Nearly one million new cases of heart failure are diagnosed annually worldwide, making it the most rapidly growing cardiovascular disorder.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo